MK-1084 for Lung Cancer

This trial tests a new treatment called MK-1084 for individuals with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Researchers aim to determine if MK-1084, combined with other drugs, can safely shrink or eliminate tumors. The study examines the cancer's response to MK-1084 when paired with treatments like cetuximab, sacituzumab govitecan, or patritumab deruxtecan. Suitable participants have NSCLC with a specific KRAS mutation, have tried 1-2 other treatments, and have experienced cancer progression. As a Phase 1, Phase 2 trial, this research focuses on understanding how the treatment works in people and measuring its effectiveness in an initial, smaller group.

The trial information does not specify if you need to stop taking your current medications. However, if you are on immunosuppressive therapy or steroids, you may need to stop them 7 days before starting the study treatment.

Previous studies combining MK-1084 with cetuximab demonstrated a manageable safety profile, meaning most side effects were mild and treatable. Patients with advanced cancers, including lung cancer, tolerated this combination well.

For MK-1084 and sacituzumab tirumotecan (sac-TMT), past research on sac-TMT has shown it is generally safe when combined with other cancer drugs. This suggests it might also be well-tolerated with MK-1084, although specific safety data for this exact combination is not yet available.

Regarding MK-1084 combined with patritumab deruxtecan, studies have shown that patritumab deruxtecan is safe for lung cancer patients and has manageable side effects when used with other treatments. This provides some confidence in its safety when combined with MK-1084, but further research is needed for confirmation.

Researchers are excited about MK-1084 for lung cancer because it works differently than standard therapies like chemotherapy and targeted drugs. Unlike traditional treatments, MK-1084 is combined with innovative agents like Cetuximab, Sacituzumab tirumotecan (Sac-TMT), and Patritumab deruxtecan (HER3-DXd), each targeting different cancer pathways. These combinations aim to attack cancer cells more precisely and effectively, potentially leading to better outcomes and fewer side effects. This approach could offer new hope for patients, especially those who have not responded well to existing treatments.

Research has shown that MK-1084 holds promise for treating non-small cell lung cancer (NSCLC). In this trial, participants may receive MK-1084 combined with cetuximab, which has shrunk tumors in nearly half of the patients, achieving a 46% response rate, and is generally safe. Another treatment option in this trial is MK-1084 combined with sacituzumab tirumotecan (Sac-TMT), which has improved outcomes when used with other therapies, helping 84.2% of patients avoid cancer progression for at least six months. Additionally, MK-1084 combined with patritumab deruxtecan (HER3-DXd) has effectively overcome resistance to treatment in some lung cancer types, allowing patients to live longer without their cancer worsening. Each of these treatment combinations offers potential benefits for advanced NSCLC.¹²³⁵⁶